Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Hyperthyroidism | Research article

Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction

Authors: Guodong Yang, Ya Wang, Aiqun Ma, Tingzhong Wang

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Subclinical thyroid dysfunction whose typical patterns include subclinical hypothyroidism and subclinical hyperthyroidism, has been indicated to be associated with an increased risk of heart failure (HF). However, the relationship between subclinical thyroid dysfunction and the clinical outcomes of HF patients is uncertain. This meta-analysis was conducted to assess the association between subclinical thyroid dysfunction and the clinical outcomes of HF patients.

Methods

Pubmed, Embase, Web of Science and Cochrane Central Register of Clinical Trials were searched for eligible studies published up to August 1, 2018 which reported the association between subclinical thyroid dysfunction and the clinical outcomes of HF patients. The pooled hazard ratio (HR) with the corresponding 95% confidence interval (CI) was used to assess the association.

Results

Fourteen studies met the eligibility criteria and a total of 21,221 patients with heart failure were included in the meta-analysis. Compared with HF patients with euthyroidism, the pooled HR of subclinical hypothyroidism for all-cause mortality was 1.45 (95% CI 1.26–1.67) in a randomized effects model with mild heterogeneity (I2 = 40.1, P = 0.073). The pooled HR of subclinical hypothyroidism for cardiac death and/or hospitalization was 1.33 (1.17–1.50) in a randomized effects model with moderate heterogeneity (I2 = 69.4, P < 0.001). Subclinical hyperthyroid can increase the risk of all-cause mortality without heterogeneity (HR 1.31, 95% CI 1.10–1.55, I2 = 25.5%, P = 0.225) but have no influence on the risk of cardiac death and/or hospitalization (HR 1.03, 95% CI 0.87–1.23, I2 = 0.0%, P = 0.958). These significant adverse associations were also retained in subgroup analysis. Sensitivity analysis demonstrated the stability of the results of our meta-analysis.

Conclusions

Both subclinical hypothyroidism and subclinical hyperthyroidism are associated with adverse prognosis in patients with HF. Subclinical thyroid dysfunction may be a useful and promising predictor for the long-term prognosis in HF patients.
Literature
1.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.PubMedCrossRef
2.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, F. American College of Cardiology, G. American Heart Association Task Force on Practice. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.PubMedCrossRef
3.
Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010;10:105.PubMedPubMedCentralCrossRef
4.
Lewis KS, Butler J, Bauersachs J, Sandner P. The three-decade long journey in heart failure drug development. Handb Exp Pharmacol. 2017;243:1–14.PubMed
5.
6.
7.
Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–9.PubMedCrossRef
8.
Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NF, De Marchi D, Lombardi M, L’Abbate A, Iervasi G. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol. 2005;45(3):439–45.PubMedCrossRef
9.
Biondi B, Palmieri EA, Lombardi G, Fazio S. Subclinical hypothyroidism and cardiac function. Thyroid. 2002;12(6):505–10.PubMedCrossRef
10.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–34.PubMedCrossRef
11.
12.
Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76–131.PubMedCrossRef
13.
Surks MI, Boucai L. Age- and race-based serum thyrotropin reference limits. J Clin Endocrinol Metab. 2010;95(2):496–502.PubMedCrossRef
14.
Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.PubMedCrossRef
15.
Ro K, Yuen AD, Du L, Ro CC, Seger C, Yeh MW, Leung AM, Rhee CM. Impact of hypothyroidism and heart failure on hospitalization risk. Thyroid. 2018; 28(9):1094–1100.
16.
Sato Y, Yoshihisa A, Kimishima Y, Kiko T, Watanabe S, Kanno Y, Abe S, Miyata M, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Ishida T, Takeishi Y. Subclinical hypothyroidism is associated with adverse prognosis in heart failure patients. Can J Cardiol. 2018;34(1):80–7.PubMedCrossRef
17.
Hayashi T, Hasegawa T, Kanzaki H, Funada A, Amaki M, Takahama H, Ohara T, Sugano Y, Yasuda S, Ogawa H, Anzai T. Subclinical hypothyroidism is an independent predictor of adverse cardiovascular outcomes in patients with acute decompensated heart failure. ESC Heart Fail. 2016;3(3):168–76.PubMedPubMedCentralCrossRef
18.
Wang W, Guan H, Gerdes AM, Iervasi G, Yang Y, Tang YD. Thyroid status, cardiac function, and mortality in patients with idiopathic dilated cardiomyopathy. J Clin Endocrinol Metab. 2015;100(8):3210–8.PubMedCrossRef
19.
Sharma AK, Vegh E, Orencole M, Miller A, Blendea D, Moore S, Lewis GD, Singh JP, Parks KA, Heist EK. Association of hypothyroidism with adverse events in patients with heart failure receiving cardiac resynchronization therapy. Am J Cardiol. 2015;115(9):1249–53.PubMedCrossRef
20.
Li X, Yang X, Wang Y, Ding L, Wang J, Hua W. The prevalence and prognostic effects of subclinical thyroid dysfunction in dilated cardiomyopathy patients: a single-center cohort study. J Card Fail. 2014;20(7):506–12.PubMedCrossRef
21.
Perez AC, Jhund PS, Stott DJ, Gullestad L, Cleland JG, van Veldhuisen DJ, Wikstrand J, Kjekshus J, McMurray JJ. Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). JACC Heart Fail. 2014;2(1):35–40.PubMedCrossRef
22.
Chen S, Shauer A, Zwas DR, Lotan C, Keren A, Gotsman I. The effect of thyroid function on clinical outcome in patients with heart failure. Eur J Heart Fail. 2014;16(2):217–26.PubMedCrossRef
23.
van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, Maggioni AP, Voors AA. Co-morbidities in patients with heart failure: an analysis of the European heart failure pilot survey. Eur J Heart Fail. 2014;16(1):103–11.PubMedCrossRef
24.
Azemi T, Bhavnani S, Kazi F, Coleman CI, Guertin D, Kluger J, Clyne CA. Prognostic impact of thyroid stimulating hormone levels in patients with cardiomyopathy. Conn Med. 2013;77(7):409–15.PubMed
25.
Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Johnson GW, Poole JE, Lee KL, Bardy GH. Thyroid function in heart failure and impact on mortality. JACC Heart Fail. 2013;1(1):48–55.PubMedPubMedCentralCrossRef
26.
Rhee CM, Curhan GC, Alexander EK, Bhan I, Brunelli SM. Subclinical hypothyroidism and survival: the effects of heart failure and race. J Clin Endocrinol Metab. 2013;98(6):2326–36.PubMedPubMedCentralCrossRef
27.
Frey A, Kroiss M, Berliner D, Seifert M, Allolio B, Guder G, Ertl G, Angermann CE, Stork S, Fassnacht M. Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol. 2013;168(1):300–5.PubMedCrossRef
28.
Iacoviello M, Guida P, Guastamacchia E, Triggiani V, Forleo C, Catanzaro R, Cicala M, Basile M, Sorrentino S, Favale S. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr Pharm Des. 2008;14(26):2686–92.PubMedCrossRef
29.
Ning N, Gao D, Triggiani V, Iacoviello M, Mitchell JE, Ma R, Zhang Y, Kou H. Prognostic role of hypothyroidism in heart failure: a meta-analysis. Medicine (Baltimore). 2015;94(30):e1159.CrossRef
30.
Triggiani V, Iacoviello M. Thyroid disorders in chronic heart failure: from prognostic set-up to therapeutic management. Endocr Metab Immune Disord Drug Targets. 2013;13(1):22–37.PubMedCrossRef
31.
Triggiani V, Iacoviello M, Monzani F, Puzzovivo A, Guida P, Forleo C, Ciccone MM, Catanzaro R, Tafaro E, Licchelli B, Giagulli VA, Guastamacchia E, Favale S. Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone. Endocr Metab Immune Disord Drug Targets. 2012;12(1):86–94.PubMedCrossRef
32.
Marcisz C, Jonderko G, Wroblewski T, Kurzawska G, Mazur F. Left ventricular mass in patients with hyperthyroidism. Med Sci Monit. 2006;12(11):CR481–6.PubMed
33.
Marcisz C, Kucharz EJ, Jonderko G, Wojewodka J. The systolic function of the left ventricle of the heart in patients with hyperthyroidism during therapy. Pol Arch Med Wewn. 2001;105(2):131–8.PubMed
34.
Ozmen B, Ozmen D, Parildar Z, Mutaf I, Bayindir O. Serum N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr Res. 2007;32(1–2):1–8.PubMedCrossRef
35.
Monzani F, Di Bello V, Caraccio N, Bertini A, Giorgi D, Giusti C, Ferrannini E. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86(3):1110–5.PubMedCrossRef
36.
Di Bello V, Monzani F, Giorgi D, Bertini A, Caraccio N, Valenti G, Talini E, Paterni M, Ferrannini E, Giusti C. Ultrasonic myocardial textural analysis in subclinical hypothyroidism. J Am Soc Echocardiogr. 2000;13(9):832–40.PubMedCrossRef
37.
Biondi B, Fazio S, Palmieri EA, Carella C, Panza N, Cittadini A, Bone F, Lombardi G, Sacca L. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1999;84(6):2064–7.PubMedCrossRef
38.
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, E.S.C.S.D. Group. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.PubMedCrossRef
39.
Li JH, Safford RE, Aduen JF, Heckman MG, Crook JE, Burger CD. Pulmonary hypertension and thyroid disease. Chest. 2007;132(3):793–7.PubMedCrossRef
40.
Vakilian F, Attaran D, Shegofte M, Lari S, Ghare S. Assessment of thyroid function in idiopathic pulmonary hypertension. Res Cardiovasc Med. 2016;5(2):e29361.PubMedPubMedCentralCrossRef
41.
Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37(1):183–8.PubMedCrossRef
42.
Fabregat-Andres O, Estornell-Erill J, Ridocci-Soriano F, Garcia-Gonzalez P, Bochard-Villanueva B, Cubillos-Arango A, Espriella-Juan Rde L, Facila L, Morell S, Cortijo J. Prognostic value of pulmonary vascular resistance estimated by cardiac magnetic resonance in patients with chronic heart failure. Eur Heart J Cardiovasc Imaging. 2014;15(12):1391–9.PubMedCrossRef
43.
Duntas LH, Papanastasiou L, Mantzou E, Koutras DA. Incidence of sideropenia and effects of iron repletion treatment in women with subclinical hypothyroidism. Exp Clin Endocrinol Diabetes. 1999;107(6):356–60.PubMedCrossRef
44.
Horton L, Coburn RJ, England JM, Himsworth RL. The haematology of hypothyroidism. Q J Med. 1976;45(177):101–23.PubMed
45.
46.
Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, Muller B. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis. 2003;166(2):379–86.PubMedCrossRef
47.
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med. 2000;132(4):270–8.PubMedCrossRef
48.
Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump MP, Newman AB, Cornuz J, Franklyn JA, Westendorp RG, Vittinghoff E, Gussekloo J, Thyroid Studies C. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–74.PubMedPubMedCentralCrossRef
49.
Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31–50.PubMedCrossRef
50.
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D’Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249–52.PubMedCrossRef
51.
Osman F, Gammage MD, Sheppard MC, Franklyn JA. Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? J Clin Endocrinol Metab. 2002;87(3):963–7.PubMedCrossRef
52.
Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, Filetti S, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85(12):4701–5.PubMed
53.
Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137(11):904–14.PubMedCrossRef
54.
Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab. 2000;85(1):159–64.PubMedCrossRef
Metadata
Title
Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction
Authors
Guodong Yang
Ya Wang
Aiqun Ma
Tingzhong Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-019-1055-x

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue

Case report

Left ventricular apical hypertrophy in a transplanted heart: a case report

Research article

Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure

Research article

Epidemiology and risk factors of patients with types of acute coronary syndrome presenting to a tertiary care hospital in Sri Lanka

Correction

Correction to: “in-vitro examination of the positive inotropic effect of caffeine and taurine, the two most frequent active ingredients of energy drinks”

Research article

Usefulness of apical area index to predict left ventricular thrombus in patients with systolic dysfunction: a novel index from cardiac magnetic resonance

Research article

Low expression of PRMT5 in peripheral blood may serve as a potential independent risk factor in assessments of the risk of stable CAD and AMI

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits